Sage Journals: Discover world-class research

Abstract

Vascular complications associated with type 2 diabetes confer significant morbidity and mortality. Atherosclerosis develops much earlier and progresses more rapidly than in subjects without diabetes. The clustering of cardiovascular risk factors associated with type 2 diabetes is mainly responsible for accelerated atherosclerotic disease. While statins remain the primary lipid-modifying therapy, the pharmacological profile of the fibrates suggests potential as an alternative or additional treatment for reducing the risk of atherosclerotic vascular complications in type 2 diabetes.

Keywords

atherosclerosis dyslipidaemia fibrates type 2 diabetes

References

1. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100–07.

2. Stamler J Vaccaro O , Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44.

3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.

4. Mietinnen H Lehto S , Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69–75.

5. Clarkson P Celermajer DS , Donald AE et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996;28:573–9.

6. Falk E Shah PK , Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71.

7. Yusuf S Hawken S , Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.

8. Assmann G Carmena R , Cullen P et al. for the International Task Force for the Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk. A worldwide view. Circulation 1999;83:17F–21F.

9. Nigro J Osman N , Dart AM , Little PJ. Insulin resistance and atherosclerosis. Endocrine Rev 2006;27:242–59.

10.

10. Kim J Montagnani M , Koh KK , Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 2006;113:1888–904.

11.

11. Saydah SH Eberhardt MS , Loria CM , Brancati LF. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001;24:447–53.

12.

12. Siegel RD Cupples A , Schaefer EJ , Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring study. Metabolism 1996;45:1267–72.

13.

13. Ryden L Standl E , Bartnik M et al. on behalf of the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007;28:88–136.

14.

14. Chait A Barzg RL , Tribble DL et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350–6.

15.

15. Galeano NF Milne R , Marcel YL et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 1994;269:511–19.

16.

16. Nigon F Lesnik P , Rouis RM , Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32:1741–53.

17.

17. Carmena R Duriez P , Fruchart CJ. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004;109(23 suppl 1):III2–III7.

18.

18. Sobel BE Woodcock-Mitchell J , Schneider DJ et al. Increased plasminogen activator inhibitor type1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213–21.

19.

19. Nesto RW Rutter KM. Impact of the atherosclerotic process in patients with diabetes. Acta Diabetol 2002;39:S22–S28.

20.

20. Dzau VJ. Atherosclerosis and hypertension: mechanisms and interrelationships. J Cardiovasc Pharmacol 1990;15(suppl 5):S59–S64.

21.

21. Sjoholm J Nystrom T Endothelial inflammation in insulin resistance. Lancet 2005;365:610–12.

22.

22. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–26.

23.

23. Wilson AM Ryan MC , Boyle JA. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006;106:291–7.

24.

24. Lobbes MB Lutgens E , Heeneman S et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 2006;187:18–25.

25.

25. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease 2003. Available from http://www.athero.org

26.

26. American Diabetes Association.

Standards of medical care in diabetes-2006.

Diabetes Care 2006;29:S4–S42.

27.

27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16.

28.

28. Colhoun HM Betteridge DJ , Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96.

29.

29. Baigent C Keech A , Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.

30.

30. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1–13.

31.

31. Fazio S Linton FM. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atherosclerosis Rep 2004;6:148–57.

32.

32. Birjmohun RS Hutten BA , Kastelein JJP , Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185–97.

33.

33. Rubins HB Robins SJ , Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–18.

34.

34. Frick MH Elo O , Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237–45.

35.

35. Keech A Simes RJ , Barter P et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61.

36.

36. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905–10.

37.

37. Elkeles RS Diamond JR , Poulter C et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Prevention (SENDCAP) Study. Diabetes Care 1998;21:641–8.

38.

38. Athyros VG Papageorgiou AA , Athyrou VV et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198–202.

39.

39. Despres J-P , Lemieux I , Salomon H et al. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12 week randomized trial. J Intern Med 2002;251:490–9.

40.

40. Guerin M Bruckert E , Dolphin PJ et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16:763–72.

41.

41. Feher MD Caslake M , Foxton J et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395–9.

42.

42. Vakkilainen J Steiner G , Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation 2003;107:1733–7.

43.

43. Zambon A Hokanson JE , Brown G , Brunzell DJ. Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959–64.

44.

44. Barbier O Pineda Torra I , Dugay Y et al. Pleiotrophic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:717–26.

45.

45. Devchand P Keller H , Peters J et al. The PPARα-leucotriene B4 pathway to inflammation control. Nature 1996;384:39–43.

46.

46. Staels B Koenig W , Habib A et al. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998;393:790–3.

47.

47. Marx M Sukhova GK , Collins T , Libby P , Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125–31.

48.

48. Koskinen P Mantarri M , Manninen V et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820–5.

49.

49. Rubins HB Robins SJ , Collins D et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597–604.

50.

50. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21–7.

51.

51. Arcavi L Behar S , Caspi A et al. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am Heart J 2004;147:239–51.

52.

52. Tenenbaum A Motro M , Fisman EZ , Tanne D , Boyko V , Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154–61.

53.

53. Saha SA. Fibrates in the prevention of cardiovascular events in dyslipdemic patients: a meta-analysis of randomized placebo-controlled clinical trials. J Am Coll Cardiol 2007;49: Abstract 1002–12.

54.

54. Zhu S Su G , Meng HQ. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem 2006;52:2036–42.

55.

55. ACCORD Study Group , Buse JB Bigger JT , Byington RP . Action to Control Cardiovascular Risk in Diabetes trial: design and methods. Am J Cardiol 2007;99(12A):21i–33i.

56.

56. Alsheikh-Ali AA , Kuvin JT , Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935–8.

57.

57. Ballantyne CM Corsini A , Davidson MH et al. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553–64.

58.

58. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408–16.

59.

59. Jones PH Davidson HM. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120–2.

60.

60. Corsini A Bellosta S , Davidson HM. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96(suppl):44K–49K.

61.

61. Prueksaritanont T Subramanian R , Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505–12.

62.

62. Davidson MH Armani A , McKenney JM , Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(suppl):3C–18C.

Atherosclerosis in type 2 diabetes: a role for fibrate therapy?

Abstract

Keywords

References